MDClone Team (company pr pic)
MDClone, an Israeli medtech startup and digital health company, raised $63 million in a Series C round of funding led by two new investors Warburg Pincus, a leading global growth investor, and Viola Growth, Israel’s leading growth fund.
Israel Startup Nation is known for a wide variety of high tech fields, from cyber security to new green technologies. One of the areas that it is also known for is medtech, which refers to just about any newly developed medical technology, from the devices used by doctors to new types of software for managing doctors’ files and so on. So MDClone is in good company. Just one example of the many Israeli medtech startups making it big is Nucleix, which offers a liquid biopsy that it says can detect cancer early, and has raised $77 million in investments to date.
Founded in 2016 by Luz Erez, and CEO Ziv Ofek, MDClone provides clinicians and healthcare professionals with the ability to explore healthcare data independently and without barriers. The MDClone ADAMS Platform is a powerful data analytics environment, encouraging self-service data exploration and action across teams in a healthcare ecosystem – resulting in operational efficiencies, revenue growth and proactive care for patients around the world.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
MDClone says that the company will use the new funding to accelerate the expansion of its “transformative” healthcare data solutions by investing in new regional markets, continuing to develop the existing platform and expanding into new vertical markets including Life Science and Real World Evidence (“RWE”). The FDA explains that RWE is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real world data (RWD).
–
Connect with MDClone at #ViVE2022!
Discover a fundamentally different approach to unlocking healthcare data:
+ Interact with all patient data from any source
+ Leverage structureless data
+ Collaborate using #syntheticdataNow booking meetings:https://t.co/72n42gkhbg pic.twitter.com/ZUJX66YIDk
— MDClone (@MDClone_) February 28, 2022
“Our mission from the start was to help the healthcare ecosystem use data to improve care delivery and health. Through our journey, we’ve seen great examples around the world where innovation, passion, and technology combine to drive better outcomes. With our technology and growing customer base, we are focused on continuing our global mission and are excited to accelerate the development of new capabilities and in new markets,” said Ziv Ofek, MDClone Co-Founder and CEO.
“We’ve been looking to invest in the digital health space for a while and were fascinated with MDClone and the immense opportunity it brings to the healthcare system by the democratization of healthcare data without the risk of exposing individuals’ data. The company has shown great progress in the past year and an even bigger vision that we believe can transform the way doctors around the world can treat patients and improve care,” said Eran Westman, General Partner, Viola Growth.
